Olumiant® ▼ (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Olumiant Summary of Product Characteristics (SmPC)

Olumiant® ▼ (baricitinib): Lactose

Olumiant tablets do not contain lactose.

Further information

The active ingredient of Olumiant is Baricitinib. 1

The tablet cores contain2

  • cellulose, microcrystalline

  • croscarmellose sodium

  • magnesium stearate

  • mannitol

The film coating contains2

  • iron oxide red (E172)

  • lecithin (soya) (E322)

  • macrogol

  • poly (vinyl alcohol)

  • talc

  • titanium dioxide (E171)

This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, i.e., essentially “sodium- free”.2

Olumiant is contraindicated in case of hypersensitivity to the active substance or to any of the excipients.2

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

2. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: November 02, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question